THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC: Form 990, tax year 2018
View the entire original 990 at ProPublica ↗
- Organization
- THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC (EIN 06-1504413)
- Tax period
- 2018-01-01 to 2018-12-31
- Filed
- 2019-10-23
- IRS object ID
- 201932969349300618
- Schema version
- 2018v3.1
- Source
- Download XML · Original 990 at ProPublica
Every field in the e-filed return. Faint text is the IRS element name, for citing.
- Return header
- Form 990
- Schedule A
- Schedule B
- Schedule D
- Schedule F
- Schedule G
- Schedule I
- Schedule J
- Schedule M
- Schedule O
- Schedule R
Return header ReturnHeader
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return | 2019-10-23T10:10:30-05:00 | ReturnTs |
| Tax Period End | 2018-12-31 | TaxPeriodEndDt |
Preparer Firm PreparerFirmGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Firm EIN | 271728945 | PreparerFirmEIN |
Preparer Firm Name PreparerFirmName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | PKF O'CONNOR DAVIES LLP | BusinessNameLine1Txt |
Preparer US Address PreparerUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 3001 SUMMER STREET 5TH FLOOR EAST | AddressLine1Txt |
| City | STAMFORD | CityNm |
| State Abbreviation | CT | StateAbbreviationCd |
| ZIP | 06905 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return Type | 990 | ReturnTypeCd |
| Tax Period Begin | 2018-01-01 | TaxPeriodBeginDt |
Filer Filer
| Field | Value | IRS element (for citing) |
|---|---|---|
| EIN | 061504413 | EIN |
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | THE MULTIPLE MYELOMA RESEARCH | BusinessNameLine1Txt |
| Business Name Line2 | FOUNDATION INC | BusinessNameLine2Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Control | MULT | BusinessNameControlTxt |
| Phone | 2039721250 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 383 MAIN AVE NO 5TH FL | AddressLine1Txt |
| City | NORWALK | CityNm |
| State Abbreviation | CT | StateAbbreviationCd |
| ZIP | 06851 | ZIPCd |
Business Officer BusinessOfficerGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | ROBERT MIANI | PersonNm |
| Person Title | TREASURER/CFO | PersonTitleTxt |
| Phone | 2039721250 | PhoneNum |
| Signature | 2019-10-23 | SignatureDt |
| Discuss With Paid Preparer | Yes (1) | DiscussWithPaidPreparerInd |
Preparer Person PreparerPersonGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Person | GARRETT M HIGGINS | PreparerPersonNm |
| PTIN | P00543209 | PTIN |
| Phone | 2033232400 | PhoneNum |
| Preparation | 2019-10-22 | PreparationDt |
Filing Security Information FilingSecurityInformation
IP Address IPAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| I Pv4 Address | 65.51.112.58 | IPv4AddressTxt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| IP | 2019-10-23 | IPDt |
| IP Tm | 10:10:27 | IPTm |
| IP Timezone | ED | IPTimezoneCd |
| Filing License Type | P | FilingLicenseTypeCd |
| At Submission Creation Device Id | DA39A3EE5E6B4B0D3255BFEF95601890AFD80709 | AtSubmissionCreationDeviceId |
| At Submission Filing Device Id | 9616F4B14A694591D1E716C270910E6FA5556DA3 | AtSubmissionFilingDeviceId |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Tax | 2018 | TaxYr |
| Build TS | 2019-02-21 02:37:17Z | BuildTS |
Form 990 IRS990
| Field | Value | IRS element (for citing) |
|---|---|---|
| Principal Officer | PAUL GIUSTI | PrincipalOfficerNm |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 383 MAIN AVE NO 5TH FL | AddressLine1Txt |
| City | NORWALK | CityNm |
| State Abbreviation | CT | StateAbbreviationCd |
| ZIP | 06851 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gross Receipts | $46,523,587 | GrossReceiptsAmt |
| Group Return For Affiliates | 0 | GroupReturnForAffiliatesInd |
| Organization501c3 | Yes (X) | Organization501c3Ind |
| Website Address | WWW.THEMMRF.ORG | WebsiteAddressTxt |
| Type Of Organization Corp | Yes (X) | TypeOfOrganizationCorpInd |
| Formation | 1998 | FormationYr |
| Legal Domicile State | CT | LegalDomicileStateCd |
| Activity Or Mission | SEE SCHEDULE O | ActivityOrMissionDesc |
| Voting Members Governing Body | 20 | VotingMembersGoverningBodyCnt |
| Voting Members Independent | 18 | VotingMembersIndependentCnt |
| Total Employee | 51 | TotalEmployeeCnt |
| Total Volunteers | 280 | TotalVolunteersCnt |
| Total Gross UBI | $0 | TotalGrossUBIAmt |
| Net Unrelated Bus Txbl Incm | $0 | NetUnrelatedBusTxblIncmAmt |
| PY Contributions Grants | $44,515,691 | PYContributionsGrantsAmt |
| CY Contributions Grants | $41,335,585 | CYContributionsGrantsAmt |
| PY Program Service Revenue | $3,005,435 | PYProgramServiceRevenueAmt |
| CY Program Service Revenue | $3,610,454 | CYProgramServiceRevenueAmt |
| PY Investment Income | $445,834 | PYInvestmentIncomeAmt |
| CY Investment Income | $1,125,389 | CYInvestmentIncomeAmt |
| PY Other Revenue | -$2,275,935 | PYOtherRevenueAmt |
| CY Other Revenue | -$1,899,168 | CYOtherRevenueAmt |
| PY Total Revenue | $45,691,025 | PYTotalRevenueAmt |
| CY Total Revenue | $44,172,260 | CYTotalRevenueAmt |
| PY Grants And Similar Paid | $8,106,761 | PYGrantsAndSimilarPaidAmt |
| CY Grants And Similar Paid | $5,457,988 | CYGrantsAndSimilarPaidAmt |
| PY Benefits Paid To Members | $0 | PYBenefitsPaidToMembersAmt |
| CY Benefits Paid To Members | $0 | CYBenefitsPaidToMembersAmt |
| PY Salaries Comp Emp Bnft Paid | $6,135,807 | PYSalariesCompEmpBnftPaidAmt |
| CY Salaries Comp Emp Bnft Paid | $6,235,917 | CYSalariesCompEmpBnftPaidAmt |
| PY Total Prof Fndrsng Expns | $0 | PYTotalProfFndrsngExpnsAmt |
| CY Total Prof Fndrsng Expns | $0 | CYTotalProfFndrsngExpnsAmt |
| CY Total Fundraising Expense | $3,667,932 | CYTotalFundraisingExpenseAmt |
| PY Other Expenses | $16,294,030 | PYOtherExpensesAmt |
| CY Other Expenses | $24,548,454 | CYOtherExpensesAmt |
| PY Total Expenses | $30,536,598 | PYTotalExpensesAmt |
| CY Total Expenses | $36,242,359 | CYTotalExpensesAmt |
| PY Revenues Less Expenses | $15,154,427 | PYRevenuesLessExpensesAmt |
| CY Revenues Less Expenses | $7,929,901 | CYRevenuesLessExpensesAmt |
| Total Assets BOY | $56,487,907 | TotalAssetsBOYAmt |
| Total Assets EOY | $69,711,900 | TotalAssetsEOYAmt |
| Total Liabilities BOY | $15,606,042 | TotalLiabilitiesBOYAmt |
| Total Liabilities EOY | $21,894,561 | TotalLiabilitiesEOYAmt |
| Net Assets Or Fund Balances BOY | $40,881,865 | NetAssetsOrFundBalancesBOYAmt |
| Net Assets Or Fund Balances EOY | $47,817,339 | NetAssetsOrFundBalancesEOYAmt |
| Info In Schedule O Part III | Yes (X) | InfoInScheduleOPartIIIInd |
| Mission | AS A PATIENT-FOUNDED ORGANIZATION, THE MMRF STANDS TOGETHER WITH THOSE WHO ARE BATTLING MULTIPLE MYELOMA PATIENTS, FAMILIES, PHYSICIANS, RESEARCHERS, AND INVESTORS. AT THE SAME TIME, THE MMRF STANDS APART WITH ITS INNOVATIVE APPROACH. THE MMRF GENERATES, INTERPRETS, AND ACTIVATES THE LARGEST COLLECTION OF HIGH QUALITY DATA AND PLACES IT IN THE PUBLIC DOMAIN. THE MMRF ORCHESTRATES THE PEOPLE, PROGRAMS, AND TECHNOLOGIES NECESSARY TO SPEED THE DISCOVERY OF A CURE. | MissionDesc |
| Significant New Program Srvc | 0 | SignificantNewProgramSrvcInd |
| Significant Change | 0 | SignificantChangeInd |
| Expense | $7,904,453 | ExpenseAmt |
| Grant | $4,403,988 | GrantAmt |
| Revenue | $277,528 | RevenueAmt |
| Desc | THE MULTIPLE MYELOMA RESEARCH FOUNDATION (MMRF) SUPPORTS INVESTIGATORS AND SCIENTIFIC PROJECTS THROUGH A NUMBER OF RESEARCH GRANTS. THE GOAL OF THIS INITIATIVE IS TO ACCELERATE THE DEVELOPMENT OF THERAPEUTIC APPROACHES FOR MYELOMA THROUGH OUR UNIQUE END-TO-END MODEL THAT SUPPORTS EFFORTS IN BASIC SCIENCE, OR TRANSLATION RESEARCH.IN 2017 THE MMRF AWARDED MULTI-YEAR GRANTS FOR THREE NEW PROGRAMS. IN DATA ANALYTICS & ANALYSIS, MMRF AWARDED $1 MILLION TO INVESTIGATORS FOR OUR ANSWER FUND, WHICH WILL LEVERAGE THE LANDMARK MMRF COMMPASS STUDY TO IDENTIFY THE NEXT GENERATION OF THERAPEUTIC TARGETS AND/OR PATHWAYS OR BIOMARKERS FOR HIGH-RISK MULTIPLE MYELOMA (MM) PATIENTS. IN IMMUNOTHERAPY, $7 MILLION WAS AWARDED TO CREATE THE IMMUNE NETWORKS OF EXCELLENCE. THESE MULTICENTER, AND MULTINATIONAL, RESEARCH PARTNERSHIPS OF WORLD-CLASS SCIENTISTS AND CLINICIANS WILL ACCELERATE RESEARCH INTO THE ROLE OF THE PATIENT IMMUNE SYSTEM IN MYELOMA BIOLOGY AND DISEASE PROGRESSION, AND CHARACTERIZE THE CHANGES IN THE IMMUNE SYSTEM ASSOCIATED WITH THE PATIENT'S RESPONSE OR RESISTANCE TO THERAPY, AND IDENTIFY AND DEVELOP NOVEL IMMUNOTHERAPIES AND IMMUNOTHERAPY STRATEGIES. THESE INVESTIGATIVE NETWORKS WILL ALSO COLLECT AND ANALYZE A WIDE RANGE OF KEY IMMUNOLOGICAL DATA FROM PATIENTS AT DIFFERENT DISEASE STAGES AND IMMUNOTHERAPIES THAT WILL BE THE BASIS OF IMMUNE DATABANK.THE THIRD NEW INITIATIVE IS THE MMRF PREVENTION PROJECT, WHICH FOCUSES ON DETERMINING WHY THE PRECURSOR CONDITIONS MGUS AND SMOLDERING (SMM) QUICKLY PROGRESS TO MM IN SOME PATIENTS AND HOW TO IDENTIFY THIS HIGH-RISK POPULATION. $4 MILLION WAS AWARDED TO FIVE INSTITUTIONS FOR WORK ON THE MMRF PREVENTION PROJECT. | Desc |
Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $6,921,548 | ExpenseAmt |
| Grant | $1,054,000 | GrantAmt |
| Revenue | $3,610,454 | RevenueAmt |
| Desc | THE MULTIPLE MYELOMA RESEARCH CONSORTIUM, LLC. (MMRC) IS A SUBSIDIARY OF THE MULTIPLE MYELOMA RESEARCH FOUNDATION. THE MMRC IS THE FIRST RESEARCH MODEL THAT BRINGS TOGETHER 25 LEADING ACADEMIC CENTERS WITH INDUSTRY PARTNERS TO CONDUCT HIGHLY COLLABORATIVE PHASE 1 AND PHASE 2 CLINICAL TRIALS OF NOVEL COMPOUNDS AND COMBINATION TREATMENTS FOR MULTIPLE MYELOMA. ALL CENTERS ARE DRIVEN BY HIGHLY DEFINED METRICS THAT MANDATE ACCOUNTABILITY AND STRONGLY PROMOTE TEAM SCIENCE. THERE ARE CURRENTLY SEVERAL TREATMENTS IN THE PIPELINE, INCLUDING THOSE THAT TARGET GENOMIC MARKERS, IMMUNOTHERAPIES, AND NOVEL AGENTS AND MECHANISMS. IN 2018, MMRF THROUGH MMRC OPENED 4 CLINICAL TRIALS AND ENROLLED OVER 200 PATIENTS ACROSS 25 TRIALS. FROM ITS INCEPTION, MMRC HAS ENROLLED OVER 2,000 PATIENTS ACROSS MORE THAN 80 CLINICAL TRIALS. | Desc |
Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $6,271,265 | ExpenseAmt |
| Desc | THE MMRF LONGITUDINAL STUDY (COMMPASS) COMMENCED IN 2011 AND HAS BEEN EXTENDED THROUGH 2023. MMRF IS THE SPONSOR OF A PERSONALIZED MEDICINE INITIATIVE IN WHICH 1,153 NEWLY DIAGNOSED PATIENTS HAVE BEEN ENROLLED TO DATE THROUGH 108 SITES (I.E., HOSPITALS, ACADEMIC MEDICAL CENTERS AND OTHER COMMUNITY HEALTH CENTERS) ACROSS NORTH AMERICA AND EUROPE. THIS IS AN OBSERVATIONAL STUDY, RATHER THAN AN INTERVENTIONAL ONE WITH EXPERIMENTAL DRUGS BEING TESTED. BIOSPECIMENS (LIKE BLOOD AND BONE MARROW SAMPLES) ARE COLLECTED FROM THE PATIENTS PERIODICALLY OVER THE COURSE OF THEIR TREATMENT ALONG WITH CORRELATING CLINICAL DATA. THE STANDARD OF CARE (I.E., DRUGS AND TREATMENT) FOR EACH PATIENT IS DETERMINED BY SUCH PATIENT'S PERSONAL PHYSICIAN. THE TISSUE SAMPLES COLLECTED ARE PLACED IN A BIOBANK. AN UNRELATED, THIRD PARTY, NOT-FOR-PROFIT BIOMEDICAL RESEARCH INSTITUTE THEN PERFORMS LABORATORY TESTS ON A PORTION OF EACH OF THE SAMPLES RESULTING IN GENOMIC DATA ABOUT EACH PATIENT. OUR GOAL IS TO BUILD AND ANALYZE THE LARGEST FULLY ACCESSIBLE CLINICO-GENOMIC DATASET OF ANY CANCER. THE FINDINGS CANNOT BE PATENTED AND ALL THE DATA ARE PLACED ON A PUBLIC PORTAL (THE MMRF RESEARCHER GATEWAY). THE RESULTING DATA REPOSITORY IS THE MOST COMPREHENSIVE CATALOG OF MULTIPLE MYELOMA AND CONTAINS THE GREATEST AMOUNT OF WHOLE GENOME SEQUENCING DATA OF ANY CANCER, ACCESSIBLE TO ANY RESEARCHER IN THE WORLD. IT WILL PROVIDE FAR MORE INFORMATION THAN IS AVAILABLE FROM CURRENT CANCER TISSUE BANKS THAT TYPICALLY INCLUDE ONLY ONE SAMPLE PER PATIENT.IN 2015, COMMPASS WAS CLOSED TO NEW ENROLLMENT WITH THE AFOREMENTIONED 1,153 PATIENTS WHO ARE BEING FOLLOWED FOR A PERIOD OF 8 YEARS UNTIL 2023. SAMPLE/DATA SHARING COLLABORATIONS WITH GROUPS LIKE ECOG, (THE "EASTERN COOPERATIVE ONCOLOGY GROUP") ARE EXPECTED TO ACCRUE APPROXIMATELY 100 PATIENTS BY THE END OF 2019. | Desc |
Prog Srvc Accom Acty Other ProgSrvcAccomActyOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $10,798,358 | ExpenseAmt |
| Desc | IN ADDITION TO THE PROGRAM EXPENSES DESCRIBED ABOVE, CORRESPONDING ACTIVITIES IN ALIGNMENT WITH THE OVERALL GOALS OF THE ORGANIZATION ARE ALSO SUPPORTED. THESE INCLUDE A PORTFOLIO OF CUTTING-EDGE RESEARCH PROGRAMS IN BASIC SCIENCE, WHICH IDENTIFIES NEW TARGETS THROUGH GENOMICS AND PROTEOMICS RESEARCH; VALIDATION STUDIES, WHICH IDENTIFY NEW COMPOUNDS AND COMBINATIONS IN RESEARCH MODELS BASED ON HIGH-PRIORITY TARGETS; AND INNOVATIVE CLINICAL TRIALS OF NOVEL AND COMBINATION TREATMENTS. ALSO, THE MMRF DEVELOPS AND IMPLEMENTS EXTENSIVE EDUCATIONAL PROGRAMMING FOR HEALTHCARE PROFESSIONALS AND FOR PATIENTS AND CAREGIVERS. | Desc |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Other Prog Srvc Expense | $10,798,358 | TotalOtherProgSrvcExpenseAmt |
| Total Program Service Expenses | $31,895,624 | TotalProgramServiceExpensesAmt |
| Described In Section501c3 | Yes (1) | DescribedInSection501c3Ind |
| Schedule B Required | Yes (1) | ScheduleBRequiredInd |
| Political Campaign Acty | 0 | PoliticalCampaignActyInd |
| Lobbying Activities | 0 | LobbyingActivitiesInd |
| Subject To Proxy Tax | 0 | SubjectToProxyTaxInd |
| Donor Advised Fund | 0 | DonorAdvisedFundInd |
| Conservation Easements | 0 | ConservationEasementsInd |
| Collections Of Art | 0 | CollectionsOfArtInd |
| Credit Counseling | 0 | CreditCounselingInd |
| Temp Or Permanent Endowments | 0 | TempOrPermanentEndowmentsInd |
| Report Land Building Equipment | Yes (1) | ReportLandBuildingEquipmentInd |
| Report Investments Other Sec | 0 | ReportInvestmentsOtherSecInd |
| Report Program Related Invst | 0 | ReportProgramRelatedInvstInd |
| Report Other Assets | 0 | ReportOtherAssetsInd |
| Report Other Liabilities | Yes (1) | ReportOtherLiabilitiesInd |
| Include FIN48 Footnote | Yes (1) | IncludeFIN48FootnoteInd |
| Independent Audit Fincl Stmt | 0 | IndependentAuditFinclStmtInd |
| Consolidated Audit Fincl Stmt | Yes (1) | ConsolidatedAuditFinclStmtInd |
| School Operating | 0 | SchoolOperatingInd |
| Foreign Office | 0 | ForeignOfficeInd |
| Foreign Activities | Yes (1) | ForeignActivitiesInd |
| More Than5000 K To Org | Yes (1) | MoreThan5000KToOrgInd |
| More Than5000 K To Individuals | 0 | MoreThan5000KToIndividualsInd |
| Professional Fundraising | 0 | ProfessionalFundraisingInd |
| Fundraising Activities | Yes (1) | FundraisingActivitiesInd |
| Gaming Activities | 0 | GamingActivitiesInd |
| Operate Hospital | 0 | OperateHospitalInd |
| Grants To Organizations | Yes (1) | GrantsToOrganizationsInd |
| Grants To Individuals | Yes (1) | GrantsToIndividualsInd |
| Schedule J Required | Yes (1) | ScheduleJRequiredInd |
| Tax Exempt Bonds | 0 | TaxExemptBondsInd |
| Engaged In Excess Benefit Trans | 0 | EngagedInExcessBenefitTransInd |
| PY Excess Benefit Trans | 0 | PYExcessBenefitTransInd |
| Loan Outstanding | 0 | LoanOutstandingInd |
| Grant To Related Person | 0 | GrantToRelatedPersonInd |
| Business Rln With Org Mem | 0 | BusinessRlnWithOrgMemInd |
| Business Rln With Fam Mem | 0 | BusinessRlnWithFamMemInd |
| Business Rln With Officer Ent | 0 | BusinessRlnWithOfficerEntInd |
| Deductible Non Cash Contri | Yes (1) | DeductibleNonCashContriInd |
| Deductible Art Contribution | 0 | DeductibleArtContributionInd |
| Terminate Operations | 0 | TerminateOperationsInd |
| Partial Liquidation | 0 | PartialLiquidationInd |
| Disregarded Entity | Yes (1) | DisregardedEntityInd |
| Related Entity | 0 | RelatedEntityInd |
| Related Organization Ctrl Ent | 0 | RelatedOrganizationCtrlEntInd |
| Trnsfr Exmpt Non Chrtbl Rltd Org | 0 | TrnsfrExmptNonChrtblRltdOrgInd |
| Activities Conducted Prtshp | 0 | ActivitiesConductedPrtshpInd |
| Schedule O Required | Yes (1) | ScheduleORequiredInd |
| IRP Document | 66 | IRPDocumentCnt |
| IRP Document W2 G | 0 | IRPDocumentW2GCnt |
| Employee | 51 | EmployeeCnt |
| Employment Tax Returns Filed | Yes (1) | EmploymentTaxReturnsFiledInd |
| Unrelated Bus Incm Over Limit | 0 | UnrelatedBusIncmOverLimitInd |
| Foreign Financial Account | 0 | ForeignFinancialAccountInd |
| Prohibited Tax Shelter Trans | 0 | ProhibitedTaxShelterTransInd |
| Taxable Party Notification | 0 | TaxablePartyNotificationInd |
| Nondeductible Contributions | 0 | NondeductibleContributionsInd |
| Quid Pro Quo Contributions | Yes (1) | QuidProQuoContributionsInd |
| Quid Pro Quo Contri Discl | Yes (1) | QuidProQuoContriDisclInd |
| Form8282 Property Disposed Of | 0 | Form8282PropertyDisposedOfInd |
| Rcv Fnds To Pay Prsnl Bnft Cntrct | 0 | RcvFndsToPayPrsnlBnftCntrctInd |
| Pay Premiums Prsnl Bnft Cntrct | 0 | PayPremiumsPrsnlBnftCntrctInd |
| Indoor Tanning Services | 0 | IndoorTanningServicesInd |
| Subj To Tax Rmnrtn Ex Prcht Pymt | 0 | SubjToTaxRmnrtnExPrchtPymtInd |
| Subject To Excs Tax Net Invst Inc | 0 | SubjectToExcsTaxNetInvstIncInd |
| Info In Schedule O Part VI | Yes (X) | InfoInScheduleOPartVIInd |
| Governing Body Voting Members | 20 | GoverningBodyVotingMembersCnt |
| Independent Voting Member | 18 | IndependentVotingMemberCnt |
| Family Or Business Rln | Yes (1) | FamilyOrBusinessRlnInd |
| Delegation Of Mgmt Duties | 0 | DelegationOfMgmtDutiesInd |
| Change To Org Documents | 0 | ChangeToOrgDocumentsInd |
| Material Diversion Or Misuse | 0 | MaterialDiversionOrMisuseInd |
| Members Or Stockholders | 0 | MembersOrStockholdersInd |
| Election Of Board Members | 0 | ElectionOfBoardMembersInd |
| Decisions Subject To Approva | 0 | DecisionsSubjectToApprovaInd |
| Minutes Of Governing Body | Yes (1) | MinutesOfGoverningBodyInd |
| Minutes Of Committees | Yes (1) | MinutesOfCommitteesInd |
| Officer Mailing Address | 0 | OfficerMailingAddressInd |
| Local Chapters | 0 | LocalChaptersInd |
| Form990 Provided To Gvrn Body | Yes (1) | Form990ProvidedToGvrnBodyInd |
| Conflict Of Interest Policy | Yes (1) | ConflictOfInterestPolicyInd |
| Annual Disclosure Covered Prsn | Yes (1) | AnnualDisclosureCoveredPrsnInd |
| Regular Monitoring Enfrc | Yes (1) | RegularMonitoringEnfrcInd |
| Whistleblower Policy | Yes (1) | WhistleblowerPolicyInd |
| Document Retention Policy | Yes (1) | DocumentRetentionPolicyInd |
| Compensation Process CEO | Yes (1) | CompensationProcessCEOInd |
| Compensation Process Other | Yes (1) | CompensationProcessOtherInd |
| Investment In Joint Venture | 0 | InvestmentInJointVentureInd |
| States Where Copy Of Return Is Fld | AL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | AR | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | CA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | FL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | GA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | IL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | KS | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | KY | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MD | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MN | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MS | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MO | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NH | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NJ | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NY | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NC | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | OR | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | PA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | RI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | SC | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | TN | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | UT | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | VA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | WI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | WV | StatesWhereCopyOfReturnIsFldCd |
| Own Website | Yes (X) | OwnWebsiteInd |
| Other Website | Yes (X) | OtherWebsiteInd |
| Upon Request | Yes (X) | UponRequestInd |
Books In Care Of Detail BooksInCareOfDetail
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | ROBERT MIANI | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Phone | 2036520207 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 383 MAIN AVE 5TH FLOOR | AddressLine1Txt |
| City | NORWALK | CityNm |
| State Abbreviation | CT | StateAbbreviationCd |
| ZIP | 06851 | ZIPCd |
Form990 Part VII Section A Form990PartVIISectionAGrp (30 entries)
| TitleTitleTxt | Average Hours Per WeekAverageHoursPerWeekRt | Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd | OfficerOfficerInd | Reportable Comp From OrgReportableCompFromOrgAmt | Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt | Other CompensationOtherCompensationAmt | Key EmployeeKeyEmployeeInd | Highest Compensated EmployeeHighestCompensatedEmployeeInd |
|---|---|---|---|---|---|---|---|---|
| MICHAEL MORTIMER | ||||||||
| CHAIRMAN | 2.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | ||
| LORI TAUBER-MARCUS | ||||||||
| VICE CHAIRMAN | 2.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | ||
| PAUL GIUSTI | ||||||||
| PRESIDENT & CEO | 45.00 | Yes (X) | Yes (X) | $604,080 | $0 | $13,137 | ||
| KENNETH ANDERSON MD | ||||||||
| BOARD MEMBER | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| KAREN ANDREWS | ||||||||
| BOARD MEMBER | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| TOM CONHEENEY | ||||||||
| BOARD MEMBER | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| RODNEY GILMORE | ||||||||
| BOARD MEMBER | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| W DANA LAFORGE | ||||||||
| BOARD MEMBER | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| DAVID LUCCHINO | ||||||||
| BOARD MEMBER | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| HUGH MARTIN | ||||||||
| BOARD MEMBER | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| SUSAN MARVIN | ||||||||
| BOARD MEMBER | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| GERALD MCDOUGALL | ||||||||
| BOARD MEMBER | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| WILLIAM MCKIERNAN | ||||||||
| BOARD MEMBER | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| DAVID PARKINSON MD | ||||||||
| BOARD MEMBER | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| MARIE PINIZZOTTO MD | ||||||||
| BOARD MEMBER | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| MICHAEL REINERT | ||||||||
| BOARD MEMBER | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| RODGER RINEY | ||||||||
| BOARD MEMBER | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| STEVEN SHAK | ||||||||
| BOARD MEMBER | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| MERYL ZAUSNER | ||||||||
| BOARD MEMBER | 2.00 | Yes (X) | $0 | $0 | $0 | |||
| KATHY GIUSTI | ||||||||
| FOUNDER & CHIEF MISSION OFFICER | 45.00 | Yes (X) | $251,584 | $0 | $1,820 | |||
| ROBERT MIANI | ||||||||
| TREASURER/CFO | 45.00 | Yes (X) | $303,326 | $0 | $19,984 | |||
| KAREN DIETZ | ||||||||
| SECRETARY/IN-HOUSE COUNSEL | 45.00 | Yes (X) | $152,727 | $0 | $34,319 | |||
| ANNE QUINN YOUNG | ||||||||
| CHIEF MARKETING & DEV. OFFICER | 45.00 | $229,709 | $0 | $14,785 | Yes (X) | |||
| DANIEL AUCLAIR | ||||||||
| CHIEF SCIENTIFIC OFFICER | 45.00 | $235,335 | $0 | $11,382 | Yes (X) | |||
| LAURA GILMAN | ||||||||
| VP OF EVENTS | 45.00 | $162,252 | $0 | $27,728 | Yes (X) | |||
| CHRISTOPHER WILLIAMS | ||||||||
| VP OF BUSINESS DEVELOPMENT | 45.00 | $195,515 | $0 | $33,907 | Yes (X) | |||
| MARGARET FURLONG | ||||||||
| ASSOC. DIR. OF CLINICAL OPS. | 45.00 | $155,487 | $0 | $32,284 | Yes (X) | |||
| ALICIA O'NEILL | ||||||||
| DIR. OF EVENTS BUSINESS DEVELOPMENT | 45.00 | $153,050 | $0 | $17,629 | Yes (X) | |||
| KAREN WOOLLEY | ||||||||
| CLINICAL OPERATIONS MANAGER | 45.00 | $142,200 | $0 | $6,766 | Yes (X) | |||
| MARY DEROME | ||||||||
| DIR. OF MED. COMMS & EDUC. | 45.00 | $138,612 | $0 | $9,154 | Yes (X) | |||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Reportable Comp From Org | $2,723,877 | TotalReportableCompFromOrgAmt |
| Tot Reportable Comp Rltd Org | $0 | TotReportableCompRltdOrgAmt |
| Total Other Compensation | $222,895 | TotalOtherCompensationAmt |
| Indiv Rcvd Greater Than100 K | 20 | IndivRcvdGreaterThan100KCnt |
| Former Ofcr Employees Listed | 0 | FormerOfcrEmployeesListedInd |
| Total Comp Greater Than150 K | Yes (1) | TotalCompGreaterThan150KInd |
| Compensation From Other Srcs | 0 | CompensationFromOtherSrcsInd |
Contractor Compensation ContractorCompensationGrp (5 entries)
| Address Line1ContractorAddress/USAddress/AddressLine1Txt | CityContractorAddress/USAddress/CityNm | State AbbreviationContractorAddress/USAddress/StateAbbreviationCd | ZIPContractorAddress/USAddress/ZIPCd | ServicesServicesDesc | CompensationCompensationAmt |
|---|---|---|---|---|---|
| IQVIA INC | |||||
| 100 IMS DRIVE | PARSIPANNY | NJ | 07054 | STRATEGIC PLANNING | $2,123,500 |
| TGEN | |||||
| 445 N FIFTH STREET | PHOENIX | AZ | 85004 | TISSUE & GENE ANALYSIS | $1,948,977 |
| PRECISION ONCOLOGY | |||||
| 200 ROUTE 21 NORTH SUITE 102 | FLEMMING | NJ | 08822 | CONTRACT RESEARCH | $1,546,260 |
| EVENT 360 INC | |||||
| 55 E JACKSON BOULEVARD SUITE 1010 | CHICAGO | IL | 60604 | 5K EVENT MANAGEMENT | $1,458,894 |
| REDMEDED LLC | |||||
| 5 GREAT VALLEY PARKWAY SUITE 221 | MALVERN | PA | 19355 | CONTINUING MEDICAL EDUCATION | $947,701 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Cntrct Rcvd Greater Than100 K | 29 | CntrctRcvdGreaterThan100KCnt |
| Fundraising | $9,183,859 | FundraisingAmt |
| All Other Contributions | $32,151,726 | AllOtherContributionsAmt |
| Noncash Contributions | $659,602 | NoncashContributionsAmt |
| Total Contributions | $41,335,585 | TotalContributionsAmt |
Program Service Revenue ProgramServiceRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Desc | RESEARCH & CLINICAL TRIALS | Desc |
| Business | 541610 | BusinessCd |
| Total Revenue Column | $3,610,454 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $3,610,454 | RelatedOrExemptFuncIncomeAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Program Service Revenue | $3,610,454 | TotalProgramServiceRevenueAmt |
Investment Income InvestmentIncomeGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $1,090,003 | TotalRevenueColumnAmt |
| Exclusion | $1,090,003 | ExclusionAmt |
Royalties Revenue RoyaltiesRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $277,528 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $277,528 | RelatedOrExemptFuncIncomeAmt |
Gross Amount Sales Assets GrossAmountSalesAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $46,217 | SecuritiesAmt |
Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $10,831 | SecuritiesAmt |
Gain Or Loss GainOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $35,386 | SecuritiesAmt |
Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $35,386 | TotalRevenueColumnAmt |
| Exclusion | $35,386 | ExclusionAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Fundraising Gross Income | $163,800 | FundraisingGrossIncomeAmt |
| Contri Rpt Fundraising Event | $9,183,859 | ContriRptFundraisingEventAmt |
| Fundraising Direct Expenses | $2,340,496 | FundraisingDirectExpensesAmt |
Net Incm From Fundraising Evt NetIncmFromFundraisingEvtGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | -$2,176,696 | TotalRevenueColumnAmt |
| Exclusion | -$2,176,696 | ExclusionAmt |
Total Revenue TotalRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $44,172,260 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $3,887,982 | RelatedOrExemptFuncIncomeAmt |
| Unrelated Business Revenue | $0 | UnrelatedBusinessRevenueAmt |
| Exclusion | -$1,051,307 | ExclusionAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Info In Schedule O Part IX | Yes (X) | InfoInScheduleOPartIXInd |
Grants To Domestic Orgs GrantsToDomesticOrgsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $5,202,988 | TotalAmt |
| Program Services | $5,202,988 | ProgramServicesAmt |
Grants To Domestic Individuals GrantsToDomesticIndividualsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $225,000 | TotalAmt |
| Program Services | $225,000 | ProgramServicesAmt |
Foreign Grants ForeignGrantsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $30,000 | TotalAmt |
| Program Services | $30,000 | ProgramServicesAmt |
Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,062,170 | TotalAmt |
| Program Services | $1,451,104 | ProgramServicesAmt |
| Management And General | $166,704 | ManagementAndGeneralAmt |
| Fundraising | $444,362 | FundraisingAmt |
Other Salaries And Wages OtherSalariesAndWagesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $3,444,803 | TotalAmt |
| Program Services | $2,424,032 | ProgramServicesAmt |
| Management And General | $278,475 | ManagementAndGeneralAmt |
| Fundraising | $742,296 | FundraisingAmt |
Pension Plan Contributions PensionPlanContributionsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $105,858 | TotalAmt |
| Program Services | $74,490 | ProgramServicesAmt |
| Management And General | $8,557 | ManagementAndGeneralAmt |
| Fundraising | $22,811 | FundraisingAmt |
Other Employee Benefits OtherEmployeeBenefitsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $236,022 | TotalAmt |
| Program Services | $166,083 | ProgramServicesAmt |
| Management And General | $19,080 | ManagementAndGeneralAmt |
| Fundraising | $50,859 | FundraisingAmt |
Payroll Taxes PayrollTaxesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $387,064 | TotalAmt |
| Program Services | $272,368 | ProgramServicesAmt |
| Management And General | $31,290 | ManagementAndGeneralAmt |
| Fundraising | $83,406 | FundraisingAmt |
Fees For Services Legal FeesForServicesLegalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $305,281 | TotalAmt |
| Program Services | $214,820 | ProgramServicesAmt |
| Management And General | $24,678 | ManagementAndGeneralAmt |
| Fundraising | $65,783 | FundraisingAmt |
Fees For Services Accounting FeesForServicesAccountingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $40,345 | TotalAmt |
| Program Services | $28,390 | ProgramServicesAmt |
| Management And General | $3,261 | ManagementAndGeneralAmt |
| Fundraising | $8,694 | FundraisingAmt |
Fees For Services Other FeesForServicesOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $4,792,090 | TotalAmt |
| Program Services | $3,907,286 | ProgramServicesAmt |
| Management And General | $19,988 | ManagementAndGeneralAmt |
| Fundraising | $864,816 | FundraisingAmt |
Advertising AdvertisingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,769,554 | TotalAmt |
| Program Services | $1,159,588 | ProgramServicesAmt |
| Management And General | $10,560 | ManagementAndGeneralAmt |
| Fundraising | $599,406 | FundraisingAmt |
Office Expenses OfficeExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $394,293 | TotalAmt |
| Program Services | $280,750 | ProgramServicesAmt |
| Management And General | $30,029 | ManagementAndGeneralAmt |
| Fundraising | $83,514 | FundraisingAmt |
Information Technology InformationTechnologyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $408,198 | TotalAmt |
| Program Services | $295,453 | ProgramServicesAmt |
| Management And General | $30,758 | ManagementAndGeneralAmt |
| Fundraising | $81,987 | FundraisingAmt |
Occupancy OccupancyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $313,332 | TotalAmt |
| Program Services | $220,485 | ProgramServicesAmt |
| Management And General | $25,329 | ManagementAndGeneralAmt |
| Fundraising | $67,518 | FundraisingAmt |
Travel TravelGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $507,041 | TotalAmt |
| Program Services | $216,848 | ProgramServicesAmt |
| Management And General | $2,956 | ManagementAndGeneralAmt |
| Fundraising | $287,237 | FundraisingAmt |
Conferences Meetings ConferencesMeetingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,131,015 | TotalAmt |
| Program Services | $948,355 | ProgramServicesAmt |
| Management And General | $1,081 | ManagementAndGeneralAmt |
| Fundraising | $181,579 | FundraisingAmt |
Depreciation Depletion DepreciationDepletionGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $204,234 | TotalAmt |
| Program Services | $143,715 | ProgramServicesAmt |
| Management And General | $16,510 | ManagementAndGeneralAmt |
| Fundraising | $44,009 | FundraisingAmt |
Insurance InsuranceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $128,107 | TotalAmt |
| Program Services | $81,553 | ProgramServicesAmt |
| Management And General | $9,369 | ManagementAndGeneralAmt |
| Fundraising | $37,185 | FundraisingAmt |
Other Expenses OtherExpensesGrp (4 entries)
| DescDesc | TotalTotalAmt | Program ServicesProgramServicesAmt |
|---|---|---|
| LS STUDY | $6,271,265 | $6,271,265 |
| CLINICAL TRIALS | $5,282,136 | $5,282,136 |
| PATIENT & CLINICIAN OUT | $1,605,638 | $1,605,638 |
| GENOMIC ANALYSIS | $677,478 | $677,478 |
All Other Expenses AllOtherExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $718,447 | TotalAmt |
| Program Services | $715,799 | ProgramServicesAmt |
| Management And General | $178 | ManagementAndGeneralAmt |
| Fundraising | $2,470 | FundraisingAmt |
Total Functional Expenses TotalFunctionalExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $36,242,359 | TotalAmt |
| Program Services | $31,895,624 | ProgramServicesAmt |
| Management And General | $678,803 | ManagementAndGeneralAmt |
| Fundraising | $3,667,932 | FundraisingAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Joint Costs | Yes (X) | JointCostsInd |
Total Joint Costs TotalJointCostsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $545,539 | TotalAmt |
| Program Services | $255,837 | ProgramServicesAmt |
| Management And General | $0 | ManagementAndGeneralAmt |
| Fundraising | $289,702 | FundraisingAmt |
Cash Non Interest Bearing CashNonInterestBearingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $14,258,907 | BOYAmt |
| EOY | $4,828,497 | EOYAmt |
Savings And Temp Cash Invst SavingsAndTempCashInvstGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $13,024,327 | BOYAmt |
| EOY | $2,154,114 | EOYAmt |
Pledges And Grants Receivable PledgesAndGrantsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $6,348,349 | BOYAmt |
| EOY | $18,032,623 | EOYAmt |
Accounts Receivable AccountsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $2,341,764 | BOYAmt |
| EOY | $2,767,033 | EOYAmt |
Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $720,523 | BOYAmt |
| EOY | $882,583 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Land Bldg Equip Cost Or Other Bss | $2,404,349 | LandBldgEquipCostOrOtherBssAmt |
| Land Bldg Equip Accum Deprec | $1,117,851 | LandBldgEquipAccumDeprecAmt |
Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $467,655 | BOYAmt |
| EOY | $1,286,498 | EOYAmt |
Investments Pub Traded Sec InvestmentsPubTradedSecGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $18,684,405 | BOYAmt |
| EOY | $39,118,575 | EOYAmt |
Investments Other Securities InvestmentsOtherSecuritiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $550,000 | BOYAmt |
| EOY | $550,000 | EOYAmt |
Other Assets Total OtherAssetsTotalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $91,977 | BOYAmt |
| EOY | $91,977 | EOYAmt |
Total Assets TotalAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $56,487,907 | BOYAmt |
| EOY | $69,711,900 | EOYAmt |
Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $6,366,096 | BOYAmt |
| EOY | $10,995,491 | EOYAmt |
Grants Payable GrantsPayableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $7,316,928 | BOYAmt |
| EOY | $8,569,261 | EOYAmt |
Deferred Revenue DeferredRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $1,923,018 | BOYAmt |
| EOY | $1,596,426 | EOYAmt |
Other Liabilities OtherLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $733,383 | EOYAmt |
Total Liabilities TotalLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $15,606,042 | BOYAmt |
| EOY | $21,894,561 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Organization Follows SFAS117 | Yes (X) | OrganizationFollowsSFAS117Ind |
Unrestricted Net Assets UnrestrictedNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $34,872,587 | BOYAmt |
| EOY | $30,050,411 | EOYAmt |
Temporarily Rstr Net Assets TemporarilyRstrNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $6,009,278 | BOYAmt |
| EOY | $17,766,928 | EOYAmt |
Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $40,881,865 | BOYAmt |
| EOY | $47,817,339 | EOYAmt |
Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $56,487,907 | BOYAmt |
| EOY | $69,711,900 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Info In Schedule O Part XI | Yes (X) | InfoInScheduleOPartXIInd |
| Reconcilation Revenue Expnss | $7,929,901 | ReconcilationRevenueExpnssAmt |
| Net Unrlzd Gains Losses Invst | -$619,427 | NetUnrlzdGainsLossesInvstAmt |
| Other Changes In Net Assets | -$375,000 | OtherChangesInNetAssetsAmt |
| Info In Schedule O Part XII | Yes (X) | InfoInScheduleOPartXIIInd |
| Method Of Accounting Accrual | Yes (X) | MethodOfAccountingAccrualInd |
| Accountant Compile Or Review | 0 | AccountantCompileOrReviewInd |
| FS Audited | Yes (1) | FSAuditedInd |
FS Audited Basis FSAuditedBasisGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Consolidated Basis Fincl Stmt | Yes (X) | ConsolidatedBasisFinclStmtInd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Audit Committee | Yes (1) | AuditCommitteeInd |
| Federal Grant Audit Required | 0 | FederalGrantAuditRequiredInd |
Schedule A IRS990ScheduleA
| Field | Value | IRS element (for citing) |
|---|---|---|
| Public Organization170 | Yes (X) | PublicOrganization170Ind |
Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $29,542,535 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $29,213,174 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $37,196,531 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $44,140,691 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $41,335,585 | CurrentTaxYearAmt |
| Total | $181,428,516 | TotalAmt |
Total Calendar Year170 TotalCalendarYear170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $29,542,535 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $29,213,174 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $37,196,531 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $44,140,691 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $41,335,585 | CurrentTaxYearAmt |
| Total | $181,428,516 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Substantial Contributors Tot | $38,857,659 | SubstantialContributorsTotAmt |
| Public Support Total170 | $142,570,857 | PublicSupportTotal170Amt |
Gross Investment Income170 GrossInvestmentIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $139,672 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $145,653 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $216,547 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $373,452 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $1,090,003 | CurrentTaxYearAmt |
| Total | $1,965,327 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Support | $183,393,843 | TotalSupportAmt |
| Gross Receipts Rltd Activities | $15,168,696 | GrossReceiptsRltdActivitiesAmt |
| Public Support CY170 | 0.77740 | PublicSupportCY170Pct |
| Public Support PY170 | 0.74330 | PublicSupportPY170Pct |
| Thirty Thr Pct Suprt Tests CY170 | Yes (X) | ThirtyThrPctSuprtTestsCY170Ind |
Schedule B IRS990ScheduleB
Schedule D IRS990ScheduleD
Leasehold Improvements LeaseholdImprovementsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $642,686 | OtherCostOrOtherBasisAmt |
| Depreciation | $45,774 | DepreciationAmt |
| Book Value | $596,912 | BookValueAmt |
Equipment EquipmentGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $252,926 | OtherCostOrOtherBasisAmt |
| Depreciation | $138,538 | DepreciationAmt |
| Book Value | $114,388 | BookValueAmt |
Other Land Buildings OtherLandBuildingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $1,508,737 | OtherCostOrOtherBasisAmt |
| Depreciation | $933,539 | DepreciationAmt |
| Book Value | $575,198 | BookValueAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Book Value Land Buildings | $1,286,498 | TotalBookValueLandBuildingsAmt |
Other Liabilities Org OtherLiabilitiesOrgGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Desc | DEFERRED RENT EXPENSE PAYABLE | Desc |
| Amt | $733,383 | Amt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Liability | $733,383 | TotalLiabilityAmt |
| Footnote Text | Yes (X) | FootnoteTextInd |
| Total Rev Etc Audited Fincl Stmt | $43,694,975 | TotalRevEtcAuditedFinclStmtAmt |
| Net Unrealized Gains Invst | -$619,427 | NetUnrealizedGainsInvstAmt |
| Donated Services And Use Fclts | $495,445 | DonatedServicesAndUseFcltsAmt |
| Other Revenue | $21,697 | OtherRevenueAmt |
| Revenue Not Reported | -$102,285 | RevenueNotReportedAmt |
| Revenue Subtotal | $43,797,260 | RevenueSubtotalAmt |
| Other Revenues Not Included | $375,000 | OtherRevenuesNotIncludedAmt |
| Revenue Not Reported Fincl Stmt | $375,000 | RevenueNotReportedFinclStmtAmt |
| Total Revenue Per Form990 | $44,172,260 | TotalRevenuePerForm990Amt |
| Tot Expns Etc Audited Fincl Stmt | $36,759,501 | TotExpnsEtcAuditedFinclStmtAmt |
| Donated Services Use Fclts | $495,445 | DonatedServicesUseFcltsAmt |
| Other Expenses Included | $21,697 | OtherExpensesIncludedAmt |
| Expenses Not Reported | $517,142 | ExpensesNotReportedAmt |
| Expenses Subtotal | $36,242,359 | ExpensesSubtotalAmt |
| Expenses Not Rpt Fincl Stmt | $0 | ExpensesNotRptFinclStmtAmt |
| Total Expenses Per Form990 | $36,242,359 | TotalExpensesPerForm990Amt |
Supplemental Information Detail SupplementalInformationDetail (4 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| PART X, LINE 2: | MMRF RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS ONLY IF THOSE POSITIONS ARE MORE LIKELY THAN NOT TO BE SUSTAINED. MANAGEMENT HAS DETERMINED THAT MMRF HAD NO UNCERTAIN TAX POSITIONS THAT WOULD REQUIRE FINANCIAL STATEMENT RECOGNITION OR DISCLOSURE. |
| PART XI, LINE 2D - OTHER ADJUSTMENTS: | CONTRIBUTION REVENUE RECLASSIFICATION 21,697. |
| PART XI, LINE 4B - OTHER ADJUSTMENTS: | WRITE-OFF OF UNCOLLECTIBLE PLEDGE REPORTED ON PART XI, LINE 9 375,000. |
| PART XII, LINE 2D - OTHER ADJUSTMENTS: | CONTRIBUTION REVENUE RECLASSIFICATION 21,697. |
Schedule F IRS990ScheduleF
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (1) | GrantRecordsMaintainedInd |
Account Activities Outside US AccountActivitiesOutsideUSGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Region | NORTH AMERICA | RegionTxt |
| Offices | 0 | OfficesCnt |
| Employee | 0 | EmployeeCnt |
| Type Of Activities Conducted | GRANTMAKING | TypeOfActivitiesConductedTxt |
| Region Total Expenditures | $30,000 | RegionTotalExpendituresAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Subtotal Offices | 0 | SubtotalOfficesCnt |
| Subtotal Employees | 0 | SubtotalEmployeesCnt |
| Continuation Total Office | 0 | ContinuationTotalOfficeCnt |
| Continuation Total Employee | 0 | ContinuationTotalEmployeeCnt |
| Total Office | 0 | TotalOfficeCnt |
| Total Employee | 0 | TotalEmployeeCnt |
| Subtotal Spent | $30,000 | SubtotalSpentAmt |
| Continuation Spent | $0 | ContinuationSpentAmt |
| Total Spent | $30,000 | TotalSpentAmt |
Grants To Org Outside US GrantsToOrgOutsideUSGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Region | NORTH AMERICA | RegionTxt |
| Purpose Of Grant | SITE INVESTMENT GRANT | PurposeOfGrantTxt |
| Cash Grant | $30,000 | CashGrantAmt |
| Manner Of Cash Disbursement | CHECK | MannerOfCashDisbursementTxt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 1 | Total501c3OrgCnt |
| Total Other Org | 0 | TotalOtherOrgCnt |
| Transfer To Foreign Corp | 0 | TransferToForeignCorpInd |
| Interest In Foreign Trust | 0 | InterestInForeignTrustInd |
| Foreign Corp Ownership | 0 | ForeignCorpOwnershipInd |
| Passive Foreign Investmest Co | 0 | PassiveForeignInvestmestCoInd |
| Foreign Partnership | 0 | ForeignPartnershipInd |
| Boycott Countries | 0 | BoycottCountriesInd |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART I, LINE 2: | FormAndLineReferenceDesc |
| Explanation | MMRF RECEIVES PROGRESS REPORTS ON HOW THE GRANTED FUNDS ARE USED. MMRF CONDUCTS A REVIEW PROCESS, RANKING PROPOSED GRANTS AND AWARDING THE PROPOSED GRANT TO THE HIGHEST SCORING ORGANIZATION. | ExplanationTxt |
Schedule G IRS990ScheduleG
Fundraising Event Information FundraisingEventInformationGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Event1 | CHICAGO DINNER | Event1Nm |
| Gross Receipts Event1 | $804,574 | GrossReceiptsEvent1Amt |
| Charitable Contri Event1 | $730,199 | CharitableContriEvent1Amt |
| Gross Revenue Event1 | $74,375 | GrossRevenueEvent1Amt |
| Non Cash Prizes Event1 | $162 | NonCashPrizesEvent1Amt |
| Rent Facility Costs Event1 | $93,766 | RentFacilityCostsEvent1Amt |
| Entertainment Event1 | $99,303 | EntertainmentEvent1Amt |
| Other Direct Expenses Event1 | $85,046 | OtherDirectExpensesEvent1Amt |
| Event2 | NEW YORK DINNER | Event2Nm |
| Gross Receipts Event2 | $752,767 | GrossReceiptsEvent2Amt |
| Charitable Contri Event2 | $663,342 | CharitableContriEvent2Amt |
| Gross Revenue Event2 | $89,425 | GrossRevenueEvent2Amt |
| Non Cash Prizes Event2 | $162 | NonCashPrizesEvent2Amt |
| Rent Facility Costs Event2 | $182,577 | RentFacilityCostsEvent2Amt |
| Entertainment Event2 | $78,072 | EntertainmentEvent2Amt |
| Other Direct Expenses Event2 | $98,384 | OtherDirectExpensesEvent2Amt |
| Other Events Total | 40 | OtherEventsTotalCnt |
| Gross Receipts Other Events | $7,790,318 | GrossReceiptsOtherEventsAmt |
| Charitable Contri Other Events | $7,790,318 | CharitableContriOtherEventsAmt |
| Oth Direct Expnss Other Events | $1,703,024 | OthDirectExpnssOtherEventsAmt |
| Gross Receipts Total | $9,347,659 | GrossReceiptsTotalAmt |
| Charitable Contributions Tot | $9,183,859 | CharitableContributionsTotAmt |
| Gross Revenue Total Events | $163,800 | GrossRevenueTotalEventsAmt |
| Non Cash Prizes Total Events | $324 | NonCashPrizesTotalEventsAmt |
| Rent Fclty Costs Total Events | $276,343 | RentFcltyCostsTotalEventsAmt |
| Entertainment Total Events | $177,375 | EntertainmentTotalEventsAmt |
| Oth Direct Expnss Total Events | $1,886,454 | OthDirectExpnssTotalEventsAmt |
| Direct Expense Summary Events | $2,340,496 | DirectExpenseSummaryEventsAmt |
| Net Income Summary | -$2,176,696 | NetIncomeSummaryAmt |
Schedule I IRS990ScheduleI
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (1) | GrantRecordsMaintainedInd |
Recipient Table RecipientTable (26 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | Recipient EINRecipientEIN | IRC SectionIRCSectionDesc | Cash GrantCashGrantAmt | Purpose Of GrantPurposeOfGrantTxt | Address Line2USAddress/AddressLine2Txt |
|---|---|---|---|---|---|---|---|---|
| BARBARA ANN KARMANOS CANCER HOSPITAL | ||||||||
| 4100 JOHN R STREET | DETROIT | MI | 48201 | 201649466 | 501(C)(3) | $36,500 | SITE INVESTMENT GRANT | |
| BAYLOR RESEARCH INSTITUTE - SAMMONS CANCER CENTER | ||||||||
| PO BOX 846275 | DALLAS | TX | 75284 | 751921898 | 501(C)(3) | $22,500 | SITE INVESTMENT GRANT | |
| BETH ISREAL DEACONESS MEDICAL CENTER | ||||||||
| 330 BROOKLINE AVENUE | BOSTON | MA | 02215 | 042103881 | 501(C)(3) | $152,000 | SITE INVESTMENT GRANT, IMMUNOTHERAPY RFA GRANT | |
| CITY OF HOPE | ||||||||
| 1500 EAST DUARTE ROAD MEDICAL | DURATE | CA | 91010 | 953435919 | 501(C)(3) | $27,500 | SITE INVESTMENT GRANT | OFFICE BLD 3RD FLOOR |
| DANA FARBER CANCER INSTITUTE | ||||||||
| 44 BINEY ST | BOSTON | MA | 02115 | 042263040 | 501(C)(3) | $1,285,845 | SITE INVESTMENT GRANT, TRANSLATIONAL CORE GRANT, GENOMIC DATA ANALYSIS GRANT, PREVENTION PROGRAM GRANT, MOLDECULAR PROFILING | |
| EMORY UNIVERSITY | ||||||||
| 1365 CLIFTON RD BLDG C | ATLANTA | GA | 30322 | 580566256 | 501(C)(3) | $420,000 | SITE INVESTMENT GRANT, GENOMIC DATA ANALYSIS GRANT, PREVENTION PROGRAM GRANT | |
| HACKENSACK UNIVERSITY MEDICAL CENTER | ||||||||
| 360 ESSEX CENTER SUITE 302 | HACKENSACK | NJ | 07601 | 221487576 | 501(C)(3) | $35,000 | SITE INVESTMENT GRANT | |
| ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | ||||||||
| ONE GUSTAVE L LEVY PLACE PO BOX | NEW YORK | NY | 10029 | 136171197 | 501(C)(3) | $90,000 | SITE INVESTMENT GRANT | 1075 |
| JOHNS HOPKINS MEDICAL INSTITUTIONS | ||||||||
| 3910 KESWICK ROAD NO N4327B | BALTIMORE | MD | 21211 | 520595110 | 501(C)(3) | $750,000 | IMMUNOTHERAPY RFA GRANT | |
| LEVINE CANCER CENTER | ||||||||
| 1021 MOREHEAD MEDICAL DRIVE | CHARLOTTE | NC | 28204 | 560529945 | 501(C)(3) | $29,500 | SITE INVESTMENT GRANT | |
| MASSACHUSETTS GENERAL HOSPITAL | ||||||||
| 125 NASHUA STREET SUITE 540 | BOSTON | MA | 02114 | 046011702 | 501(C)(3) | $37,500 | SITE INVESTMENT GRANT | |
| MAYO CLINIC | ||||||||
| 4500 SAN PABLO ROAD | JACKSONVILLE | FL | 32224 | 590714831 | 501(C)(3) | $35,000 | SITE INVESTMENT GRANT | |
| MAYO CLINIC | ||||||||
| 200 FIRST STREET SW | ROCHESTER | MN | 55905 | 416011702 | 501(C)(3) | $75,000 | SITE INVESTMENT GRANT | |
| MAYO CLINIC | ||||||||
| 13400 EAST SHEA BOULEVARD | SCOTTSDALE | AZ | 85259 | 860800150 | 501(C)(3) | $32,500 | SITE INVESTMENT GRANT | |
| MEMORIAL SLOAN-KETTERING CANCER CENTER | ||||||||
| 1275 YORK AVENUE | NEW YORK | NY | 10065 | 131924236 | 501(C)(3) | $1,190,643 | SITE INVESTMENT GRANT, TRANSLATIONAL CORE GRANT, IMMUNOTHERAPY RFA GRANT, PREVENTION PROGRAM GRANT | |
| OHIO STATE UNIVERSITY RESEARCH FOUNDATION | ||||||||
| B321 STARLING LOVING HALL 320 WEST | COLUMBUS | OH | 43210 | 316401599 | 501(C)(3) | $47,500 | SITE INVESTMENT GRANT | 10TH AVENUE |
| ROCKEFELLER UNIVERSITY | ||||||||
| 1230 YORK AVENUE | NEW YORK | NY | 10065 | 131624158 | 501(C)(3) | $100,000 | PREVENTION PROGRAM GRANT | |
| SARAH CANNON RESEARCH INSTITUTE LLC | ||||||||
| 3322 WEST END ROAD SUITE 900 | NASHVILLE | TN | 37203 | 201557751 | $50,000 | SITE INVESTMENT GRANT | ||
| THE UNIVERSITY OF CHICAGO | ||||||||
| 5841 S MARYLAND AVENUE MC 2115 | CHICAGO | IL | 60637 | 362177139 | 501(C)(3) | $80,000 | SITE INVESTMENT GRANT | |
| THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER | ||||||||
| 1515 HOLCOMBE | HOUSTON | TX | 77030 | 746001118 | STATE OF TEXAS | $350,000 | PREVENTION PROGRAM GRANT | |
| UCSF MYELOMA RESEARCH PROGRAM | ||||||||
| 1855 FOLSOM STREET ROOM 423 | SAN FRANCISCO | CA | 94103 | 946036493 | 501(C)(3) | $62,500 | SITE INVESTMENT GRANT | |
| UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES | ||||||||
| 4301 W MARKHAM STREET SLOT 812 | LITTLE ROCK | AR | 72205 | 716046242 | STATE OF ARKANSAS | $120,000 | SITE INVESTMENT GRANT, PREVENTION PROGRAM GRANT | |
| UNIVERSITY OF MICHIGAN | ||||||||
| 4310 CANCER CENTER 1500 EAST | ANN ARBOR | MI | 48109 | 386006309 | 501(C)(3) | $47,500 | SITE INVESTMENT GRANT | MEDICAL CENTER DRIVE |
| UNIVERSITY OF TEXAS- SOUTHWESTERN MEDICAL CENTER | ||||||||
| 5323 HARRY HINES BOULEVARD | DALLAS | TX | 75390 | 756002868 | 501(C)(3) | $23,000 | SITE INVESTMENT GRANT | |
| VIRGINIA CANCER SPECIALISTS PC | ||||||||
| 8503 ARLINGTON BLVD SUITE 320 | FAIRFAX | VA | 22031 | 541795091 | $27,500 | SITE INVESTMENT GRANT | ||
| WASHINGTON UNIVERSITY IN ST LOUIS | ||||||||
| 660 E EUCLID AVENUE | ST LOUIS | MO | 63110 | 430653611 | 501(C)(3) | $75,500 | SITE INVESTMENT GRANT | |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 24 | Total501c3OrgCnt |
| Total Other Org | 2 | TotalOtherOrgCnt |
Grants Other Asst To Indiv In US GrantsOtherAsstToIndivInUSGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Type | FELLOWS RESEARCH AWARDS | GrantTypeTxt |
| Recipient | 3 | RecipientCnt |
| Cash Grant | $225,000 | CashGrantAmt |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART I, LINE 2: | FormAndLineReferenceDesc |
| Explanation | THERE ARE SEVERAL STEPS THAT LEAD UP TO INDIVIDUAL RESEARCH GRANTS BEING AWARDED: 1. THE OVERALL RESEARCH BUDGET IS PRESENTED TO THE MMRF BOARD. THE BUDGET IS BROKEN DOWN INTO THREE MAIN CATEGORIES WHICH INCLUDE THE FOLLOWING GRANT TYPES: A) CLINIC: CLINICAL- SITE INVESTMENT GRANTS, CLINICAL FUNDING AGREEMENT GRANTS, PRECISION MEDICINE GRANTS B) LEARNING NETWORK: GATEWAYS, DATA ANALYSIS INITIATIVES, TRANSLATIONAL SITE INVESTMENTS GRANTS (MMRF TRANSLATIONAL NETWORK), TRANSLATIONAL AND IMMUNE PROGRAM GRANTS, RESEARCH FELLOW GRANTS. C) DATA BANK: MMRF-SPONSORED LONGITUDINAL MOLECULAR AND IMMUNE STUDIES (COMMPASS AND THE MMRF CURECLOUD). THE BUDGET SPEND IS INITIALLY APPROVED BY THE PROGRAMMING COMMITTEE, AND THEN THE BOARD GIVES FINAL APPROVAL FOR THE RESEARCH SPEND. 2. DURING THE YEAR, WE HAVE MONTHLY RESEARCH SPEND MEETINGS WITH THE CEO AND CFO TO DISCUSS PROGRESS ON MAKING THE AWARDS. ADDITIONALLY, ANY CHANGES OR REFORECASTS ARE DISCUSSED. IF THERE IS A CHANGE GREATER THAN $1M THEN WE MUST GO BACK TO THE PROGRAMMING COMMITTEE TO DISCUSS. 3. THERE ARE TWO DISTINCT TYPES OF GRANTS BEING AWARDED: MORE CLASSICAL RESEARCH SUPPORT GRANTS AND CLINICAL/TRANSLATIONAL SITE SUPPORT GRANTS. THE ACTUAL AWARDS ARE MADE ACCORDING TO THE BELOW SCHEDULE: A. RESEARCH FELLOW AWARDS- QTR 3 OR QTR 4 B. CLINICAL AND TRANSLATIONAL SITE SUPPORT GRANTS QTR 4 C. OTHER GRANTS ARE MADE THROUGHOUT THE YEAR CLASSICAL RESEARCH GRANTS: CLASSICAL RESEARCH GRANTS ARE AWARDED ON THE BASIS OF THE FOLLOWING PROCESS: GRANTS ARE REVIEWED BY AN EXTERNAL GROUP OF SCIENTISTS WITH THE APPROPRIATE AREAS OF EXPERTISE. SCIENTIFIC RATINGS USE THE CURRENT NIH SCORING SYSTEM OF 1-9 WITH 1 DEMONSTRATING THE HIGHEST SCIENTIFIC MERIT AND 9 BEING THE LOWEST. EACH PROPOSAL IS EVALUATED BY TWO INDEPENDENT OUTSIDE REVIEWERS AND THE SCORES ARE AVERAGED TOGETHER. MOST GRANTS CHOSEN SCORE AT LEAST A 3 OR BETTER TO BE FUNDED. ONCE THE GRANTS ARE RATED EXTERNALLY, FINAL REVIEW IS DONE BY THE MMRF RESEARCH LEADERSHIP AND RECOMMENDATIONS ARE MADE TO THE CEO TO CONFIRM THE FINAL SELECTION. AFTER EACH GRANT TYPE AWARD IS MADE, AN AWARD LETTER IS SENT TO THE RECIPIENT AND AN EMAIL IS SENT TO THE CFO AND THE ASSOCIATE DIRECTOR OF FINANCE NOTIFYING THEM OF THE GRANTS AWARDED AND TO PROCEED WITH MAKING THE ACCRUAL FOR THE GRANT. ALSO, WE HAVE A CONFLICT OF INTEREST POLICY AND A COMMITTEE THAT REVIEWS ANY ISSUES. AFTER THE FIRST PAYMENT THE RESEARCHER SENDS IN THE REQUIRED PROGRESS REPORT TO RECEIVE REMAINING PAYMENTS. THE REPORT IS THEN REVIEWED BY OUTSIDE REVIEWERS TO ENSURE THAT THE APPROPRIATE PROGRESS WAS MADE ON THE STUDY. ONCE THE RESEARCH EMPLOYEE ASSIGNED TO GRANT COORDINATION RECEIVES NOTIFICATION FROM THE REVIEWERS, HE/SHE PREPARES A PAYMENT REQUEST FORM TO THE SR. VICE PRESIDENT OF RESEARCH TO SIGN AND THEN SENDS IT TO FINANCE FOR PROCESSING. CLINICAL/TRANSLATIONAL SITE SUPPORT GRANTS: GRANT PROPOSALS TO SUPPORT MMRF/C CLINICAL OR TRANSLATIONAL SITES ARE REVIEWED BY MMRF RESEARCH STAFF AND LEADERSHIP IN COLLABORATION WITH OUTSIDE ADVISORS. SIMILAR TO CLASSICAL GRANTS, MMRF RESEARCH LEADERSHIP THEN MAKES RECOMMENDATIONS TO THE CEO FOR FINAL APPROVAL. AFTER EACH GRANT TYPE AWARD IS APPROVED, AN AWARD LETTER IS SENT TO THE RECIPIENT AND AN EMAIL IS SENT TO THE CFO AND THE ASSOCIATE DIRECTOR OF FINANCE NOTIFYING THEM OF THE GRANTS AWARDED AND TO PROCEED WITH MAKING THE ACCRUAL FOR THE GRANT. SUCH GRANTS ARE TYPICALLY RENEWED ANNUALLY OR ARE MULTI-YEAR IN NATURE. CONTINUATION/RENEWAL IS AWARDED BASED ON MILESTONES ESTABLISHED UPON INITIATION OF THE PROGRAM. CONFLICT OF INTEREST POLICY AND COMMITTEE OVERSIGHT ALSO APPLY HERE. | ExplanationTxt |
Schedule J IRS990ScheduleJ
| Field | Value | IRS element (for citing) |
|---|---|---|
| Compensation Committee | Yes (X) | CompensationCommitteeInd |
| Form990 Of Other Organizations | Yes (X) | Form990OfOtherOrganizationsInd |
| Compensation Survey | Yes (X) | CompensationSurveyInd |
| Board Or Committee Approval | Yes (X) | BoardOrCommitteeApprovalInd |
| Severance Payment | 0 | SeverancePaymentInd |
| Supplemental Nonqual Rtr Plan | 0 | SupplementalNonqualRtrPlanInd |
| Equity Based Comp Arrngm | 0 | EquityBasedCompArrngmInd |
| Comp Based On Revenue Of Flng Org | 0 | CompBasedOnRevenueOfFlngOrgInd |
| Comp Bsd On Rev Related Orgs | 0 | CompBsdOnRevRelatedOrgsInd |
| Comp Bsd Net Earns Flng Org | 0 | CompBsdNetEarnsFlngOrgInd |
| Comp Bsd Net Earns Rltd Orgs | 0 | CompBsdNetEarnsRltdOrgsInd |
| Any Non Fixed Payments | Yes (1) | AnyNonFixedPaymentsInd |
| Initial Contract Exception | 0 | InitialContractExceptionInd |
Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (10 entries)
| TitleTitleTxt | Base Compensation Filing OrgBaseCompensationFilingOrgAmt | Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt | Bonus Filing OrganizationBonusFilingOrganizationAmount | Bonus Related OrganizationsBonusRelatedOrganizationsAmt | Other Compensation Filing OrgOtherCompensationFilingOrgAmt | Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt | Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt | Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt | Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt | Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt | Total Compensation Filing OrgTotalCompensationFilingOrgAmt | Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt | Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt | Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PAUL GIUSTI | ||||||||||||||
| PRESIDENT & CEO | $436,625 | $0 | $165,000 | $0 | $2,455 | $0 | $11,000 | $0 | $2,137 | $0 | $617,217 | $0 | $0 | $0 |
| KATHY GIUSTI | ||||||||||||||
| FOUNDER & CHIEF MISSION OFFICER | $250,000 | $0 | $0 | $0 | $1,584 | $0 | $0 | $0 | $1,820 | $0 | $253,404 | $0 | $0 | $0 |
| ROBERT MIANI | ||||||||||||||
| TREASURER/CFO | $216,746 | $0 | $66,000 | $0 | $20,580 | $0 | $9,401 | $0 | $10,583 | $0 | $323,310 | $0 | $0 | $0 |
| KAREN DIETZ | ||||||||||||||
| SECRETARY/IN-HOUSE COUNSEL | $111,639 | $0 | $17,000 | $0 | $24,088 | $0 | $6,271 | $0 | $28,048 | $0 | $187,046 | $0 | $0 | $0 |
| ANNE QUINN YOUNG | ||||||||||||||
| CHIEF MARKETING & DEV. OFFICER | $179,507 | $0 | $27,400 | $0 | $22,802 | $0 | $6,908 | $0 | $7,877 | $0 | $244,494 | $0 | $0 | $0 |
| DANIEL AUCLAIR | ||||||||||||||
| CHIEF SCIENTIFIC OFFICER | $191,692 | $0 | $27,400 | $0 | $16,243 | $0 | $9,396 | $0 | $1,986 | $0 | $246,717 | $0 | $0 | $0 |
| LAURA GILMAN | ||||||||||||||
| VP OF EVENTS | $129,510 | $0 | $17,000 | $0 | $15,742 | $0 | $6,964 | $0 | $20,764 | $0 | $189,980 | $0 | $0 | $0 |
| CHRISTOPHER WILLIAMS | ||||||||||||||
| VP OF BUSINESS DEVELOPMENT | $170,571 | $0 | $12,600 | $0 | $12,344 | $0 | $8,269 | $0 | $25,638 | $0 | $229,422 | $0 | $0 | $0 |
| MARGARET FURLONG | ||||||||||||||
| ASSOC. DIR. OF CLINICAL OPS. | $124,674 | $0 | $12,600 | $0 | $18,213 | $0 | $5,987 | $0 | $26,297 | $0 | $187,771 | $0 | $0 | $0 |
| ALICIA O'NEILL | ||||||||||||||
| DIR. OF EVENTS BUSINESS DEVELOPMENT | $128,292 | $0 | $12,000 | $0 | $12,758 | $0 | $5,385 | $0 | $12,244 | $0 | $170,679 | $0 | $0 | $0 |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART I, LINE 7 | FormAndLineReferenceDesc |
| Explanation | THE FOLLOWING EMPLOYEES RECEIVED A BONUS FROM THE ORGANIZATION. EACH BONUS WAS BASED ON THE DISCRETION OF THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS. EACH BONUS WAS BASED UPON A REVIEW OF THE INDIVIDUAL'S PERFORMANCE, AND APPROVED BY THE COMPENSATION COMMITTEE PRIOR TO BEING AWARDED. PAUL GIUSTI, PRESIDENT & CEO $165,000 ROBERT MIANI, TREASURER/CFO $66,000 KAREN DIETZ, SECRETARY & IN-HOUSE COUNSEL $17,000 ANNE QUINN YOUNG, CHIEF MARKETING & DEVELOPMENT OFFICER $27,400 DANIEL AUCLAIR, CHIEF SCIENTIFIC OFFICER $27,400 LAURA GILMAN, VP OF EVENTS $17,000 ALICIA O'NEIL, DIRECTOR OF EVENTS BUSINESS DEVELOPMENT & PARTNERSHIPS $12,000 KAREN WOOLLEY, CLINICAL OPERATIONS MANAGER $7,500 MARY DEROME, DIRECTOR OF MEDICAL COMMUNICATIONS AND EDUCATION $7,000 MARGARET FURLONG, ASSOCIATE DIRECTOR OF CLINICAL OPERATIONS $12,600 CHRISTOPHER WILLIAMS, VP OF BUSINESS DEVELOPMENT $12,600 | ExplanationTxt |
Schedule M IRS990ScheduleM
Securities Publicly Traded SecuritiesPubliclyTradedGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Non Cash Checkbox | Yes (X) | NonCashCheckboxInd |
| Contribution | 36 | ContributionCnt |
| Noncash Contributions Rpt F990 | $659,602 | NoncashContributionsRptF990Amt |
| Method Of Determining Revenues | AVG. SELLING PRICE | MethodOfDeterminingRevenuesTxt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form8283 Received | 0 | Form8283ReceivedCnt |
| Any Property That Must Be Held | 0 | AnyPropertyThatMustBeHeldInd |
| Review Process Unusual NC Gifts | Yes (1) | ReviewProcessUnusualNCGiftsInd |
| Third Parties Used | 0 | ThirdPartiesUsedInd |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART I, COLUMN (B): | FormAndLineReferenceDesc |
| Explanation | THE ORGANIZATION IS REPORTING THE NUMBER OF CONTRIBUTORS. | ExplanationTxt |
Schedule O IRS990ScheduleO
Supplemental Information Detail SupplementalInformationDetail (9 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| FORM 990, PART I, LINE 1: | MMRF ACCOMPLISHMENTS FOR 2018 THE MMRF HAS BUILT ON THE SUCCESSES OF 2017 AND HAD A BANNER YEAR IN 2018, WHICH INCLUDED THE LAUNCH OF THE FIRST PLATFORM TRIAL IN MYELOMA: - IN 2018, THE MMRF THROUGH THE MMRC OPENED FOUR CLINICAL TRIALS AND ENROLLED OVER 200 PATIENTS ACROSS 25 TRIALS. THE TOTAL NUMBER OF OPEN AND ENROLLING TRIALS REMAINS 16. FROM ITS INCEPTION, THE MMRC HAS ENROLLED OVER 2,000 PATIENTS ACROSS MORE THAN 80 TRIALS. - 1,024 COMMPASS PATIENTS HAVE HAD THEIR BASELINE MOLECULAR PROFILES COMPLETED; 242 HAD THEIR RELAPSE SAMPLES SEQUENCED AND RESULTS WERE RETURNED TO THE TREATING PHYSICIAN. MORE THAN 30 ABSTRACTS RESULTING FROM COMMPASS DATA WERE PRESENTED AT THE AMERICAN SOCIETY OF HEMATOLOGY MEETING IN DECEMBER 2018; MORE THAN 60 COMMPASS PUBLICATIONS HAVE BEEN PUBLISHED TO DATE. FIVE ABSTRACTS FROM MMRC TRIALS WERE ALSO PRESENTED AT ASH. - OVER 515 RELAPSED/REFRACTORY MM PATIENTS HAVE HAD THEIR MOLECULAR PROFILES COMPLETED THROUGH THE MMRF MOLECULAR PROFILING INITIATIVE AT UNIVERSITY OF MICHIGAN; RESULTS WERE RETURNED TO THE TREATING PHYSICIAN. - PATIENT EDUCATION PROGRAMS REACHED OVER 6000 PATIENTS AND CAREGIVERS IN 2018. - THE MMRF LAUNCHED THE MYDRUG TRIAL, THE ONLY PLATFORM TRIAL IN MULTIPLE MYELOMA, IN EARLY DECEMBER 2018. THIS TRIAL REPRESENTS THE PINNACLE OF PRECISION MEDICINE AND WAS MADE POSSIBLE USING GENOMIC FINDINGS DISCOVERED IN THE COMMPASS STUDY. PROGRESS WAS MADE IN THE THREE MULTI-MILLION DOLLAR RESEARCH INITIATIVES THAT MMRF LAUNCHED IN 2017: IN THE IMMUNOTHERAPY INITIATIVE, PROGRESS INCLUDED: - DEVELOPMENT OF A COMPREHENSIVE PIPELINE OF BIOANALYTICAL ASSAYS FOR IN-DEPTH ANALYSIS OF THE IMMUNITY IN MYELOMA PATIENTS - SUPPORT OF THE ANALYSIS OF THE TUMOR ENVIRONMENT IN MYELOMA PATIENTS WITH EARLY DISEASE TO UNDERSTAND THE ROLE THAT THEIR IMMUNE SYSTEM IN CONTROLLING DISEASE - ADVANCES IN THE DEVELOPMENT OF NEXT GENERATION IMMUNE THERAPY AGENTS AND TREATMENT STRATEGIES IN THE MMRF ANSWER FUND, RESEARCHERS HAVE DISCOVERED THAT PATIENTS WHO HAVE A TRANSLOCATION CALLED "IGL" ARE MORE PRONE TO EXPERIENCE HIGH RISK DISEASE AND IMID RESISTANCE AT THE TIME OF DIAGNOSIS. THE MMRF PREVENTION INITIATIVE IDENTIFIED NOVEL PROGNOSTIC AND HIGH-RISK BIOMARKERS IN PRECURSOR DISEASE. |
| FORM 990, PART VI, SECTION A, LINE 2 | THE FOLLOWING BOARD MEMBERS, KATHY GIUSTI, FOUNDER & CHIEF MISSION OFFICER, KAREN ANDREWS, BOARD MEMBER, AND PAUL GIUSTI, PRESIDENT & CEO, ALL HAVE A FAMILY RELATIONSHIP. |
| FORM 990, PART VI, SECTION B, LINE 11B | THE FORM 990 IS FIRST REVIEWED WITH THE CEO OF THE FOUNDATION. ONCE REVIEWED WITH THE CEO, THE FORM 990 IS EMAILED TO EACH BOARD MEMBER. EACH BOARD MEMBER REVIEWS THE FORM 990 AND IF ANY QUESTIONS ARISE, THEY ARE COMMUNICATED TO THE FOUNDATION AND ADDRESSED. AFTER ALL QUESTIONS ARE ADDRESSED, THE FORM 990 IS SUBMITTED TO THE IRS. |
| FORM 990, PART VI, SECTION B, LINE 12C | DUTY TO DISCLOSE A POTENTIAL CONFLICT OF INTEREST: ANY INTERESTED PERSON MUST DISCLOSE THE EXISTENCE OF HIS OR HER FINANCIAL INTEREST TO THE BOARD OR CONFLICTS COMMITTEE AND MUST BE GIVEN THE OPPORTUNITY TO DISCLOSE ALL MATERIAL FACTS TO THE BOARD, MEMBERS OF THE CONFLICTS COMMITTEE AND ALL MEMBERS OF ANY COMMITTEE CONSIDERING THE PROPOSED CONTRACT OR TRANSACTION. DETERMINING WHETHER A CONFLICT OF INTEREST EXISTS: AFTER DISCLOSURE OF THE FINANCIAL INTEREST AND ALL MATERIAL FACTS, AND AFTER ANY DISCUSSION WITH THE INTERESTED PERSON, THE INTERESTED PERSON SHALL LEAVE THE BOARD OR CONFLICTS COMMITTEE MEETING WHILE THE DETERMINATION OF A CONFLICT OF INTEREST IS DISCUSSED AND VOTED UPON. THE REMAINING BOARD OR CONFLICT COMMITTEE MEMBERS, AS APPLICABLE, SHALL DECIDE IF A CONFLICT OF INTEREST EXISTS. PROCEDURES FOR ADDRESSING THE CONFLICT OF INTEREST: I. AN INTERESTED PERSON MAY MAKE A PRESENTATION AT THE BOARD OR CONFLICTS COMMITTEE MEETING, BUT AFTER SUCH PRESENTATION, HE OR SHE SHALL LEAVE THE MEETING DURING THE DISCUSSION OF, AND THE VOTE ON, THE CONTRACT OR TRANSACTION THAT RESULT IN THE CONFLICT OF INTEREST. II. THE CHAIR OF THE BOARD OR CHAIRPERSON OF THE CONFLICTS COMMITTEE SHALL, IF APPROPRIATE, APPOINT A DISINTERESTED PERSON OR APPOINT OR ESTABLISH AN ADVISORY COMMITTEE TO INVESTIGATE ALTERNATIVES TO THE PROPOSED CONTRACT OR TRANSACTION. AFTER EXERCISING DUE DILIGENCE, THE BOARD OR THE CONFLICTS COMMITTEE SHALL TAKE ALL REASONABLE STEPS TO DETERMINE WHETHER THE MMRF CAN OBTAIN A MORE ADVANTAGEOUS CONTRACT OR TRANSACTION WITH REASONABLE EFFORTS FROM A PERSON OR ENTITY THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. IF A MORE ADVANTAGEOUS CONTRACT OR TRANSACTION IS NOT REASONABLY ATTAINABLE UNDER CIRCUMSTANCES THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST, THE BOARD OR CONFLICT COMMITTEE SHALL DETERMINE BY A MAJORITY VOTE, BUT NOT LESS THAN TWO, OF THE DISINTERESTED DIRECTORS OR MEMBERS THEREOF WHETHER THE CONTRACT OR TRANSACTION IS IN THE MMRF'S BEST INTEREST AND IS FAIR AND REASONABLE TO THE MMRF; PROVIDED, HOWEVER, IF SUCH CONTRACT OR TRANSACTION IS APPROVED BY DISINTERESTED DIRECTORS WHO DO NOT SATISFY A QUORUM OR VOTING REQUIREMENT APPLICABLE TO THE AUTHORIZATION OF THE ACTION BY REASON OF THE MMRF'S CERTIFICATE OF INCORPORATION, BYLAWS OR A PROVISION OF LAW, THE ACTION MUST BE INDEPENDENTLY APPROVED BY SUCH INTERESTED AND DISINTERESTED DIRECTORS AS SATISFY THE APPLICABLE QUORUM OR VOTING REQUIREMENT. VIOLATION OF THE CONFLICTS OF INTEREST POLICY: III. IF THE BOARD OR CONFLICTS COMMITTEE HAS REASONABLE CAUSE TO BELIEVE THAT A DIRECTOR, OFFICER OR COMMITTEE MEMBER HAS FAILED TO DISCLOSE ACTUAL OR POSSIBLE CONFLICTS OF INTEREST, IT SHALL INFORM SUCH PERSON OF THE BASIS FOR SUCH BELIEF AND AFFORD SUCH PERSON AN OPPORTUNITY TO EXPLAIN THE ALLEGED FAILURE TO DISCLOSE. IF, AFTER HEARING THE RESPONSE OF THE DIRECTOR, OFFICER OR COMMITTEE MEMBER AND MAKING SUCH FURTHER INVESTIGATION AS MAY BE WARRANTED IN THE CIRCUMSTANCES, THE BOARD OR CONFLICTS COMMITTEE DETERMINES THAT SUCH PERSON HAS IN FACT FAILED TO DISCLOSE AN ACTUAL OR POSSIBLE CONFLICT OF INTEREST, THE BOARD OR CONFLICTS COMMITTEE, AS APPLICABLE, SHALL TAKE APPROPRIATE DISCIPLINARY AND CORRECTIVE ACTION. |
| FORM 990, PART VI, SECTION B, LINE 15 | ALL SENIOR POSITIONS AND THEIR COMPENSATION ARE REVIEWED AND APPROVED BY THE HR COMMITTEE OF THE BOARD OF DIRECTORS. COMPENSATION FOR EMPLOYEES ARE BENCHMARKED AGAINST OTHER 501(C)(3)'S AND RESEARCH ORGANIZATIONS, THEN REVIEWED BY THE COMPENSATION COMMITTEE. THE COMPENSATION APPROVAL IS DOCUMENTED IN THE MINUTES BY THE COMMITTEE. THIS PROCESS WAS LAST UNDERTAKEN IN 2018. |
| FORM 990, PART VI, SECTION C, LINE 19 | FINANCIAL STATEMENTS, GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, FORM 990 AND FORM 1023 ARE MADE AVAILABLE FOR PUBLIC VIEWING UPON WRITTEN REQUEST AT MMRF'S HEADQUARTERS LOCATED AT 383 MAIN AVENUE, 5TH FLOOR, NORWALK, CT 06851. FORM 990 AND AUDITED FINANCIAL STATEMENTS ARE ALSO AVAILABLE AT THE ORGANIZATION'S WEBSITE: WWW.THEMMRF.ORG THE FORM 990 IS ALSO AVAILABLE ON WWW.GUIDESTAR.ORG, WWW.CHARITYNAVIGATOR.ORG, AND OTHER SIMILAR WEBSITES. |
| FORM 990, PART IX, LINE 11G | CONSULTING: PROGRAM SERVICE EXPENSES 2,800,950. MANAGEMENT AND GENERAL EXPENSES 15,067. FUNDRAISING EXPENSES 846,561. TOTAL EXPENSES 3,662,578. RECRUITING COSTS & TEMPORARY HELP: PROGRAM SERVICE EXPENSES 516,785. MANAGEMENT AND GENERAL EXPENSES 4,921. FUNDRAISING EXPENSES 18,255. TOTAL EXPENSES 539,961. OTHER PROFESSIONAL: PROGRAM SERVICE EXPENSES 589,551. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 589,551. |
| FORM 990, PART XI, LINE 9: | WRITE-OFF OF UNCOLLECTIBLE PLEDGE -375,000. |
| FORM 990, PART XII, LINE 2C: | THE MULTIPLE MYELOMA RESEARCH FOUNDATION, INC. AUDIT/FINANCE COMMITTEE RECOMMENDS THE AUDITOR TO THE BOARD, AND THE BOARD APPOINTS THE AUDITOR. THE BOARD ASSUMES RESPONSIBILITY FOR THE OVERSIGHT OF THE AUDIT OF ITS FINANCIAL STATEMENTS. THE POLICY FOR SELECTION AND OVERSIGHT OF THE INDEPENDENT AUDITORS HAS NOT CHANGED SINCE LAST YEAR. |
Schedule R IRS990ScheduleR
Id Disregarded Entities IdDisregardedEntitiesGrp (2 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | EINEIN | Primary ActivitiesPrimaryActivitiesTxt | Legal Domicile StateLegalDomicileStateCd | Total IncomeTotalIncomeAmt | End Of Year AssetsEndOfYearAssetsAmt | Business Name Line1DirectControllingEntityName/BusinessNameLine1Txt |
|---|---|---|---|---|---|---|---|---|---|
| MYELOMA INVESTMENT FUND LLC | |||||||||
| 383 MAIN AVENUE 5TH FLOOR | NORWALK | CT | 06851 | 471162865 | VENTURE PHILANTHROPY FUND | DE | $10,250,000 | $10,250,000 | THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC |
| MULTIPLE MYELOMA RESEARCH CONSORTIUM LLC | |||||||||
| 383 MAIN AVENUE 5TH FLOOR | NORWALK | CT | 06851 | 471142650 | FACILITATING OR SPONSORING CLINICAL TRIALS AND RELATED RESEARCH | CT | $4,421,117 | $1,282,300 | THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC |